Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS
2014
Fingolimod—an efficacious compound for the treatment of relapsing multiple sclerosis (MS)—functionally antagonizes the S1P receptor.1–3 This antagonism inhibits egress of T cells from secondary lymphoid tissues,2 affects B cell migration, and functionally affects germinal center reactions.4
Acknowledgment: The authors thank K. Wild for excellent support with organization of study logistics.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
8
References
5
Citations
NaN
KQI